This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The Hawaii HIV Immunology and Vaccine Core was added to the University of Hawaii at Manoa RCMI Program with supplemental funding awarded in September 2003. The overall goal of this activity is to build on existing basic science and clinical trials strengths and infrastructure to develop much-needed capacity in HIV immunology and vaccine research.
The specific aims of this activity are to: 1) expand laboratory capabilities in cellular and molecular immunology to allow greater participate in AIDS Clinical Trials Group (ACTG) trials, to expand the scope of currently funded HIV research and to serve as the HIV immunology reference laboratory for the Joint Asia Pacific/HIV/AIDS Prevention Program; 2) build institutional capacity in HIV vaccine trials research to gain entry into the HIV Vaccine Trials Network (HVTN); and 3) develop strong national and international collaborations with other institutions, lead agencies and companies involved in the testing of novel immune therapeutics and preventive HIV vaccines. This core is comprised of four distinct but interactive parts: HIV vaccine trials unit; HIV-specific antibody laboratory; CD4+ T helper laboratory; and CD8+ cytolytic T-cell laboratory.
Showing the most recent 10 out of 347 publications
